Table 2.

Comparison of patients with or without metabolic syndrome in three periods

	Pre-op MS(+) [(n:23),39%] (Mean±SD)	Pre-op MS(−) [(N:36),61%] (Mean±SD)	p	12 months MS (+) [(n:30),51.7%] (Mean±SD)	12 months MS (−) [(n:28),48.3%] (Mean±SD)	P	24 months MS (+) [(n:26),61.9%] (Mean±SD)	24 months MS(−) [(n:16),38.1%] (Mean±SD)	P
Age* (years)	57±10	49±13	0.01	56±10	48±13	0.01	58±10	49±14	0.02
Gender (female/male)	19/4	31/5	0.72	26/4	23/5	0.64	23/3	13/3	0.52
BMI* (kg/m2) (basal)	30.5±4.3	26.8±3.5	0.001	29.8±3.96	26.7±3.78	0.004	30.9±3.89	25.7±3.10	<0.001
BMI* (kg/m2) (Last control)				30.6±4.13	27.5±3.88	0.005	31.9±3.8	27.1±4.0	<0.001
Obesity# (basal)	11(47.8)	9(25)	0.08	13 (43)	7 (25)	0.14	16 (62)	2(13)	0.001
Obesity# (Last control)				14(46.6)	9(32)	0.26	17(65)	3(19)	0.002
Hypertansion#	14(60.5)	4(11,1)	<0,001	16(53)	3(11)	0.001	12(46)	2(12.5)	0.01
Hyperlipidemia#	3(11.5)	0(0)	0.08	10(33.3)	0(0)	0.08	3(11.5)	0(0)	0.08
Diabetes#	6(26)	3(8.3)	0.09	8(27)	1(4)	0.01	8(30.7)	1 (6.2)	0.03
HOMA-IR*	4. 20±5.69	2.45±3.61	0.154	3.91±5.42	2.37±3.46	0.20	3.82±4.33	1.60±0.61	0.08
Fasting Glucose* (mg/dL)	116±31	99±23	0.01	114±31	98±20	0.02	116±33	97±9.4	0.009
HbA1c* (%)	6.08±0.87	5.62±0.68	0.02	6.0±0.7	5.5±0.3	0.01	5.97±0.62	5.39±0.41	0.002
HsCRP* (mg/dL)	1.36±1.99	1.81±3.16	0.546	2.20±3.50	1.08±1.53	0.12	2.56±3.12	3.20±3.58	0.54
FT3* (pg/mL)	2.98±0.30	3.18±0.44	0.06	2.89±0.35	2.91±0.31	0.12	3.70±5.55	2.73±0.51	0.49
FT4* (ng/dL)	0.86±0.18	0.81±0.13	0.25	1.05±0.21	0.93±0.16	0.19	1.01±0.27	1.03±0.17	0.78
TSH* (mIU/mL)	2.22±3.97	1.10±1.21	0.20	1.95±3.03	4.78±1.95	0.10	6.59±8.54	1.36±2.97	0.007
Hypothyroid Patients Rate#	3(11.5)	3(8.3)	0.56	4(13)	7(25)	0.27	12 (46)	1(6)	0.002

Pre-op: preoperative; MS: metabolic syndrome; SD: standard deviation; FT3: free-T3; FT4: free-T4;

TSH: thyroid stimulanting hormone; BMI: body mass index

Datas are presented as

^*mean±SD

^#n (%)